EYPT Financials: EyePoint Inc AI Analysis

Home

Stock

EYPT

Financials

EYPT Financial

EyePoint Inc

0%

$0

As of today:Apr 07, 16:06:12 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

1.3M

Dividend yield

EPS (TTM)

-3.16

Market Cap

What is EYPT?

EyePoint Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. The company is headquartered in Watertown, Massachusetts and currently employs 165 full-time employees. The company went IPO on 2005-01-27. The firm is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.



Features

AI Copilot for Stock & Crypto

Resources

Market

Income

Balance sheet

Cash flow

Annual

Quarterly

EYPT Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021
Revenue	31	31	43	46	41	36
Revenue Growth (YoY)	-28%	-28%	-7%	12%	14%	6%
Cost of Revenue	2	2	3	4	8	8
Gross Profit	29	29	39	41	33	28
Selling, General & Admin	55	55	55	51	60	53
Research & Development	217	217	130	64	49	28
Operating Expenses	272	272	185	116	112	84
Other Non Operating Income (Expenses)	--	--	--	--	--	--
Pretax Income	-231	-231	-130	-70	-102	-58
Income Tax Expense	0	0	0	0	--	--
Net Income	-231	-231	-130	-70	-102	-58
Net Income Growth	78%	78%	86%	-31%	76%	28.99%
Shares Outstanding (Diluted)	83.13	73.25	56.29	38.9	37.32	28.76
Shares Change (YoY)	28.99%	30%	45%	4%	30%	124%
EPS (Diluted)	-2.79	-3.16	-2.32	-1.81	-2.74	-2.03
EPS Growth	38%	36%	28%	-34%	35%	-43%
Free Cash Flow	-243	-243	-130	-1	-67	-50
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	93.54%	93.54%	90.69%	89.13%	80.48%	77.77%
Operating Margin	-783.87%	-783.87%	-337.2%	-163.04%	-190.24%	-152.77%
Profit Margin	-745.16%	-745.16%	-302.32%	-152.17%	-248.78%	-161.11%
Free Cash Flow Margin	-783.87%	-783.87%	-302.32%	-2.17%	-163.41%	-138.88%
EBITDA	-241	-241	-144	-75	-76	-53
EBITDA Margin	-777.41%	-777.41%	-334.88%	-163.04%	-185.36%	-147.22%
D&A For EBITDA	2	2	1	0	2	2
EBIT	-243	-243	-145	-75	-78	-55
EBIT Margin	-783.87%	-783.87%	-337.2%	-163.04%	-190.24%	-152.77%
Effective Tax Rate	0%	0%	0%	0%	--	--

Follow-Up Questions

What are EyePoint Inc's key financial statements?



According to the latest financial statement (Form-10K), EyePoint Inc has a total asset of $363, Net loss of $-231

What are the key financial ratios for EYPT?



EyePoint Inc's Current ratio is 6.36, has a Net margin is -745.16, sales per share of $0.42.

How is EyePoint Inc's revenue broken down by segment or geography?



EyePoint Inc largest revenue segment is Ophthalmic Products, at a revenue of 43,273,000 in the most earnings release.For geography, United States is the primary market for EyePoint Inc, at a revenue of 42,049,000.

Is EyePoint Inc profitable?



no, according to the latest financial statements, EyePoint Inc has a net loss of $-231

Does EyePoint Inc have any liabilities?



yes, EyePoint Inc has liability of 57

How many outstanding shares for EyePoint Inc?



EyePoint Inc has a total outstanding shares of 82.82

EyePoint Inc (EYPT) Financial

EYPT Stock Price Chart